Country: United States
Language: English
Source: NLM (National Library of Medicine)
ROSUVASTATIN CALCIUM (UNII: 83MVU38M7Q) (ROSUVASTATIN - UNII:413KH5ZJ73)
Torrent Pharmaceuticals Limited
ROSUVASTATIN CALCIUM
ROSUVASTATIN 5 mg
ORAL
PRESCRIPTION DRUG
Rosuvastatin tablets are indicated: • To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor. • As an adjunct to diet to: o Reduce LDL-C in adults with primary hyperlipidemia. o Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults. o Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Rosuvastatin tablets are contraindi
Rosuvastatin tablets USP are supplied as: Rosuvastatin tablets USP, 5 mg are yellow colored, round, biconvex, film coated tablets debossed with '79' on one side and plain on other side. Bottles of 30 NDC 13668-179-30 Bottles of 90 NDC 13668-179-90 Bottles of 500 NDC 13668-179-05 Rosuvastatin tablets USP, 10 mg are light pink colored, round, biconvex, film coated tablets debossed with '1180' on one side and plain on other side. Bottles of 30 NDC 13668-180-30 Bottles of 90 NDC 13668-180-90 Bottles of 500 NDC 13668-180-05 Rosuvastatin tablets USP, 20 mg are light pink colored, round, biconvex, film coated tablets debossed with '1181' on one side and plain on other side. Bottles of 30 NDC 13668-181-30 Bottles of 90 NDC 13668-181-90 Bottles of 500 NDC 13668-181-05 Rosuvastatin tablets USP, 40 mg are light pink colored, oval shape, biconvex, beveled edge, film coated tablets debossed with '1182' on one side and plain on other side. Bottles of 30 NDC 13668-182-30 Bottles of 90 NDC 13668-182-90 Bottles of 500 NDC 13668-182-05 Storage Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from moisture.
Abbreviated New Drug Application
ROSUVASTATIN CALCIUM- ROSUVASTATIN CALCIUM TABLET, COATED TORRENT PHARMACEUTICALS LIMITED ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ROSUVASTATIN TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ROSUVASTATIN TABLETS. ROSUVASTATIN TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2003 RECENT MAJOR CHANGES Dosage and Administration Modifications Due to Drug Interactions (2.6) 07/2023 Contraindications, Pregnancy and Lactation (4) Removed 01/2023 Warnings and Precautions (5.2) 01/2023 Warnings and Precautions, Concomitant Coumarin Anticoagulants (5.4) Removed 01/2023 INDICATIONS AND USAGE Rosuvastatin tablets are an HMG Co-A reductase inhibitor (statin) indicated: (1) • To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults. • As an adjunct to diet to reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. DOSAGE AND ADMINISTRATION Take orally with or without food, at any time of day. (2.1) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablets, and adjust dosage if necessary. (2.1) _Adults_: Recommended dosage range is 5 to 40 mg once daily. (2.1) Read the complete document